JP2022532490A5 - - Google Patents
Info
- Publication number
- JP2022532490A5 JP2022532490A5 JP2021563296A JP2021563296A JP2022532490A5 JP 2022532490 A5 JP2022532490 A5 JP 2022532490A5 JP 2021563296 A JP2021563296 A JP 2021563296A JP 2021563296 A JP2021563296 A JP 2021563296A JP 2022532490 A5 JP2022532490 A5 JP 2022532490A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015378A JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847068P | 2019-05-13 | 2019-05-13 | |
| US62/847,068 | 2019-05-13 | ||
| PCT/US2020/032515 WO2020232019A1 (en) | 2019-05-13 | 2020-05-12 | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015378A Division JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532490A JP2022532490A (ja) | 2022-07-15 |
| JP2022532490A5 true JP2022532490A5 (cg-RX-API-DMAC7.html) | 2025-03-31 |
Family
ID=71069936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563296A Pending JP2022532490A (ja) | 2019-05-13 | 2020-05-12 | 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ |
| JP2025015378A Pending JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015378A Pending JP2025065211A (ja) | 2019-05-13 | 2025-01-31 | 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ |
Country Status (17)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
| US20210128710A1 (en) * | 2019-11-04 | 2021-05-06 | Inovio Pharmaceuticals, Inc. | Combination therapy to treat brain cancer |
| US20250270321A1 (en) * | 2021-02-23 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating lung cancer by administering a pd-1 inhibitor |
| IL309120A (en) * | 2021-07-28 | 2024-02-01 | Hoffmann La Roche | Methods and compositions for the treatment of cancer |
| WO2023019240A2 (en) | 2021-08-13 | 2023-02-16 | Inovio Pharmaceuticals Inc. | Combination therapy to treat brain cancer |
| CN115887669A (zh) * | 2022-12-19 | 2023-04-04 | 国纳之星(上海)纳米科技发展有限公司 | 一种治疗癌症的药物组合物 |
| CN115869399B (zh) * | 2022-12-28 | 2024-01-12 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用 |
| CN115845052B (zh) * | 2022-12-28 | 2023-12-29 | 广州誉衡生物科技有限公司 | 一种药物组合物和药物制剂及其在治疗结肠癌中的应用 |
| CN121127264A (zh) * | 2023-03-13 | 2025-12-12 | 瑞泽恩制药公司 | 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合 |
| CN122180519A (zh) * | 2023-11-15 | 2026-06-09 | 瑞泽恩制药公司 | 用于增强在治疗肺癌中的功效的pd-1抑制剂和lag-3抑制剂的组合 |
| AU2024391585A1 (en) * | 2023-11-30 | 2026-06-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor |
| CN119607196A (zh) * | 2023-12-13 | 2025-03-14 | 正大天晴药业集团股份有限公司 | 抗lag-3抗体与抗pd-1抗体的应用 |
| WO2025237275A1 (zh) * | 2024-05-13 | 2025-11-20 | 南京维立志博生物科技股份有限公司 | 用于治疗肿瘤的抗lag-3抗体或其抗原结合部分 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| JP3700859B2 (ja) | 1994-05-06 | 2005-09-28 | アンスティテュ ギュスタブ ルシ | Lag−3タンパク質の可溶性ポリペプチドフラクション;製造方法、治療用製剤、抗イディオタイプ抗体 |
| US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
| PT843557E (pt) | 1995-07-21 | 2003-03-31 | Applied Research Systems | Metodos para detectar indentificar isolar e etiquetar e abordar selectivamente linfocitos th1 por intermedio da proteina lag-3 |
| EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US20060240024A1 (en) | 2003-02-28 | 2006-10-26 | The Johns Hopkins University | T cell regulation |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| RS60538B1 (sr) | 2013-03-15 | 2020-08-31 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 vezujući proteini |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| WO2016191751A1 (en) | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| RU2760582C2 (ru) | 2015-09-02 | 2021-11-29 | Иммутеп С.А.С. | Анти-LAG-3 антитела |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| EP3848393A1 (en) * | 2016-05-18 | 2021-07-14 | Boehringer Ingelheim International GmbH | Antibody molecules for cancer treatment |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| US11390676B2 (en) | 2016-10-13 | 2022-07-19 | Symphogen A/S | Anti-LAG-3 antibodies and compositions |
| RS67792B1 (sr) | 2016-12-01 | 2026-03-31 | Regeneron Pharma | Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| AU2018247916B2 (en) * | 2017-04-05 | 2025-04-24 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
-
2020
- 2020-05-12 CA CA3136568A patent/CA3136568A1/en active Pending
- 2020-05-12 AU AU2020276242A patent/AU2020276242B2/en active Active
- 2020-05-12 CN CN202080035740.2A patent/CN113825527A/zh active Pending
- 2020-05-12 PH PH1/2021/552675A patent/PH12021552675A1/en unknown
- 2020-05-12 KR KR1020217034542A patent/KR20220007593A/ko active Pending
- 2020-05-12 BR BR112021021713A patent/BR112021021713A2/pt unknown
- 2020-05-12 JP JP2021563296A patent/JP2022532490A/ja active Pending
- 2020-05-12 SG SG11202111262XA patent/SG11202111262XA/en unknown
- 2020-05-12 WO PCT/US2020/032515 patent/WO2020232019A1/en not_active Ceased
- 2020-05-12 EA EA202192528A patent/EA202192528A1/ru unknown
- 2020-05-12 EP EP20731629.0A patent/EP3969040A1/en active Pending
- 2020-05-12 US US17/611,073 patent/US20220249659A1/en active Pending
- 2020-05-12 CN CN202511166496.4A patent/CN120939219A/zh active Pending
- 2020-05-12 MX MX2021013815A patent/MX2021013815A/es unknown
- 2020-05-12 MA MA055965A patent/MA55965A/fr unknown
-
2021
- 2021-10-13 ZA ZA2021/07760A patent/ZA202107760B/en unknown
- 2021-10-31 IL IL287728A patent/IL287728A/en unknown
- 2021-11-10 CL CL2021002966A patent/CL2021002966A1/es unknown
-
2025
- 2025-01-31 JP JP2025015378A patent/JP2025065211A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050618A5 (cg-RX-API-DMAC7.html) | ||
| TWI786044B (zh) | 藉由投予pd-1抑制劑治療皮膚癌之方法 | |
| JP7126941B2 (ja) | がんを治療するための抗pd-1抗体と二重特異性抗cd20/抗cd3抗体の組合せ | |
| AU2020276242B2 (en) | Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer | |
| JP2019515008A5 (cg-RX-API-DMAC7.html) | ||
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2021528423A5 (cg-RX-API-DMAC7.html) | ||
| JP2020508317A5 (cg-RX-API-DMAC7.html) | ||
| CA3129963A1 (en) | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer | |
| TW202320827A (zh) | 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合 | |
| TWI899236B (zh) | 通過投予pd-1抑制劑治療子宮頸癌的方法 | |
| NZ781933B2 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| WO2025106736A2 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer | |
| RU2021128914A (ru) | Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований | |
| TH2001007178A (th) | แอนติ-PD-1 แอนติบอดีและไบสเปซิฟิกแอนติ-CD3 x MUC16 แอนติบอดีสำหรับการผลิตตัวยาสำหรับการบำบัดหรือการยับยั้งการเจริญของเนื้องอกที่มีการแสดงออก MUC16 | |
| NZ748192B2 (en) | Methods of treating skin cancer by administering a pd-1 inhibitor |